Annette Hanson, MD, Ron Pies, MD, and Mark Komrad, MD
Authors respond to “How Should Physicians Care for Dying Patients with Amyotrophic Lateral Sclerosis?” by arguing that patients’ motives for accessing death with dignity laws should be thoroughly explored and that temporarily limiting patient autonomy can promote well-being at the end of life.
AMA J Ethics. 2018;20(11):E1107-1109. doi:
10.1001/amajethics.2018.1107.
Alexander Craig, MPhil and Elizabeth Dzeng, MD, PhD, MPH
Responding to “Added Points of Concern about Caring for Dying Patients,” authors argue that physicians’ refusal to prescribe lethal drugs in accordance with states’ death with dignity laws could damage patient-physician relationships and harm patients.
AMA J Ethics. 2018;20(11):E1110-1112. doi:
10.1001/amajethics.2018.1110.
Kristen N. Pallok and David A. Ansell’s “Should Clinicians Be Activists?” highlights how physician activists risk retaliation from “economically and socially” privileged physician leaders and organizational leadership who “have been trained to comply” with structural inequity.
AMA J Ethics. 2022;24(7):E694-696. doi:
10.1001/amajethics.2022.694.
Health system function, resilience, and sustainability are needed to help prepare trainees to lead, innovate, and prioritize a circular supply chain with low emissions.
AMA J Ethics. 2022;24(10):E951-958. doi:
10.1001/amajethics.2022.951.
Elizabeth Bromley, MD, PhD, Loretta Jones, MA, ThD, Marjorie S. Rosenthal, MD, MPH, Michele Heisler, MD, MPA, Julie A. Sochalski, PhD, RN, Deborah Koniak-Griffin, RNC, EdD, Cristina Punzalan, MPH, and Kenneth B. Wells, MD, MPH
The National Clinician Scholars Program, which will begin training physician and nursing scholars in partnership with local community-based agencies in 2016, aims to develop health care leaders who pursue community-centered goals and treat their community partners with equality and respect.
AMA J Ethics. 2015;17(12):1127-1135. doi:
10.1001/journalofethics.2015.17.12.medu1-1512.
Kevin Z. Chao, MD, Daniel J. Riskin, MD, MBA, and Thomas M. Krummel, MD
Stanford’s Biodesign Program brings together students and postgraduates in medicine, engineering, law, and business to embark on a 1- to 2-year fellowship in medical device innovation.